Study guide

9.2 Pediatric Shock States & Vasoactive / Inotropic Selection

Board Certified Pediatric Pharmacy Specialist BCPPS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure

1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation

2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles

2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development

3 Chapter 3: Neonatal Critical Care & Prematurity Complications

3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis

4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections

4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections

5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections

5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections

6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus

6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices

7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders

7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities

8 Chapter 8: Pediatric Cardiology & Hemodynamics

8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management

9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support

9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK

10 Chapter 10: Pediatric Neurology & Psychiatric Disorders

10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders

11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders

11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia

12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care

12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care

13 Chapter 13: Pediatric Medication Safety & Error Prevention

13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions

14 Chapter 14: Pediatric Compounding & Formulation Technology

14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities

15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support

15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation

16 Chapter 16: Pediatric Pain Management, Sedation & Delirium

16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies

17 Chapter 17: Biostatistics & Study Design in Pediatric Research

17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values

18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics

18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations

19 Chapter 19: Pediatric Education, Health Literacy & Communication

19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials

20 Chapter 20: Pediatric Immunizations & Public Health Advocacy

20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy

21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics

21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management

9.2 Pediatric Shock States & Vasoactive / Inotropic Selection

Key Takeaways Explain This Topic AI

Pediatric septic shock presents predominantly as 'cold shock' (~60–70% of community-acquired pediatric cases), characterized by decreased cardiac output, elevated systemic vascular resistance (SVR), prolonged capillary refill (>2 seconds), and weak peripheral pulses, requiring inotropic support rather than pure vasoconstriction.

Initial fluid resuscitation mandates the rapid administration of balanced crystalloids (Plasma-Lyte or Lactated Ringer's) in 10–20 mL/kg aliquots over 10–20 minutes, pausing immediately if clinical signs of fluid overload appear (hepatomegaly, pulmonary crackles, worsening work of breathing).

Epinephrine (0.05–0.3 mcg/kg/min) is the preferred first-line vasoactive agent for cold septic shock and cardiogenic dysfunction, whereas norepinephrine (0.05–0.3 mcg/kg/min) is the first-line choice for warm distributive shock exhibiting low SVR, flash capillary refill, and wide pulse pressure.

Dopamine is now relegated to a second-line or obsolete status in pediatric septic shock guidelines following randomized trials demonstrating higher 28-day mortality, increased healthcare-associated infections, and erratic receptor pharmacodynamics in young infants.

Refractory catecholamine-resistant shock warrants prompt initiation of stress-dose hydrocortisone (50–100 mg/m²/day or 1–2 mg/kg/day divided every 6 hours) to treat critical illness-related corticosteroid insufficiency (CIRCI), alongside milrinone (0.25–0.75 mcg/kg/min without bolus) for afterload reduction in persistent low-output states.

Last updated: September 2026

9.2 Pediatric Shock States & Vasoactive / Inotropic Selection

Shock is fundamentally defined as an acute failure of the circulatory system to deliver adequate oxygen and metabolic substrates to meet the metabolic demands of tissues ( D O 2 < V O 2 DO_2 < VO_2 D O 2 ​ < V O 2 ​ ), leading to cellular dysoxia, anaerobic metabolism, lactic acidosis, and organ system failure. In pediatric patients, the physiological reserve and compensatory mechanisms differ profoundly from adults. Pediatric stroke volume is relatively fixed due to non-compliant, immature myocardium containing fewer contractile elements per gram of tissue; cardiac output is therefore almost entirely heart rate-dependent ( C O = H R × S V CO = HR \times SV CO = H R × S V ) .

Compensated vs. Decompensated Pediatric Shock

Children maintain normal systemic blood pressure through intense compensatory peripheral vasoconstriction and tachycardia long after tissue hypoperfusion has begun. As a result, blood pressure is an exceptionally insensitive marker of early circulatory collapse. Progression of Pediatric Shock:

  • [COMPENSATED SHOCK] [DECOMPENSATED SHOCK] [CARDIOPULMONARY ARREST]
  • Heart rate: Marked tachycardia - Heart rate: Extreme tachy / brady - Severe bradycardia / Asystole
  • Blood pressure: NORMAL - Blood pressure: HYPOTENSION - Pulseless
  • Perfusion: Cool, cap refill >2s - Perfusion: Mottled / cyanotic - Apnea / Gasping
  • Pulses: Weak peripheral, full core - Pulses: Absent peripheral, thready - Immediate CPR required
  • Mentation: Irritable / lethargic - Mentation: Stupor / Coma
  • Urine: Oliguria (<1 mL/kg/h) - Urine: Anuria
  • Blood Pressure Thresholds Defining Hypotension by Age (5th Percentile)

Hypotension in pediatrics represents a late, pre-terminal event. The American Heart Association (AHA) and PALS define the lower limit of normal systolic blood pressure (5th percentile) as:

  • Term Neonates (0 to 28 days): < 60 mmHg <60 \text{ mmHg} < 60 mmHg
  • Infants (1 to 12 months): < 70 mmHg <70 \text{ mmHg} < 70 mmHg

Children (1 to 10 years): < [ 70 + ( 2 × age in years ) ] mmHg < [70 + (2 \times \text{age in years})] \text{ mmHg} < [ 70 + ( 2 × age in years )] mmHg

Example (5-year-old child): 70 + ( 2 × 5 ) = 80 mmHg 70 + (2 \times 5) = 80 \text{ mmHg} 70 + ( 2 × 5 ) = 80 mmHg

  • Children >10 years & Adolescents: < 90 mmHg <90 \text{ mmHg} < 90 mmHg
  • Categorization of Pediatric Shock States

Shock Category Primary Pathophysiology Key Clinical Manifestations Primary Pharmacotherapeutic Strategy

Hypovolemic Inadequate intravascular volume from fluid loss or hemorrhage; reduced preload ( C V P ↓ , C O ↓ , S V R ↑ CVP \downarrow, CO \downarrow, SVR \uparrow C V P ↓ , CO ↓ , S V R ↑ ) Dehydration, depressed fontanelle, dry mucous membranes, tachycardia, weak pulses Balanced crystalloids: 10–20 mL/kg boluses over 10–20 min; PRBCs (10 mL/kg) for hemorrhagic shock.

Distributive Dysregulated vasomotor tone, massive capillary leak, microvascular shunting ( S V R ↓ SVR \downarrow S V R ↓ or variable, C O CO CO variable) Septic shock, anaphylaxis, neurogenic shock; present as Cold Shock (~65%) or Warm Shock (~35%) Targeted fluid resuscitation, early vasoactive infusions ( Epinephrine for cold, Norepinephrine for warm).

Cardiogenic Intrinsic myocardial pump failure with impaired contractility ( C V P ↑ , C O ↓ , S V R ↑ CVP \uparrow, CO \downarrow, SVR \uparrow C V P ↑ , CO ↓ , S V R ↑ ) Hepatomegaly, jugular venous distention, pulmonary crackles, gallop rhythm ( S 3 S_3 S 3 ​ ), cardiomegaly Fluid restriction (5–10 mL/kg boluses with extreme caution); inotropes ( Milrinone , low-dose Epinephrine ).

Obstructive Extracardiac mechanical barrier to blood flow and ventricular filling ( C V P ↑ , C O ↓ CVP \uparrow, CO \downarrow C V P ↑ , CO ↓ ) Cardiac tamponade, tension pneumothorax, pulmonary embolism, ductal-dependent cardiac lesions Relieve mechanical obstruction (decompression, pericardiocentesis); Alprostadil (PGE1) for ductal lesions.

Critical Clinical Entity: Neonatal Ductal-Dependent Congenital Heart Defects

In neonates presenting at 1 to 2 weeks of life with profound, sudden cardiovascular collapse and cardiogenic/obstructive shock, closure of the ductus arteriosus must be presumed. Lesions dependent on systemic blood flow via the ductus include:

  • Coarctation of the aorta
  • Interrupted aortic arch
  • Critical aortic stenosis
  • Hypoplastic left heart syndrome (HLHS)

Immediate Pharmacotherapy: Alprostadil (Prostaglandin E1, PGE1) continuous IV infusion initiated at 0.05 to 0.1 mcg/kg/min 0.05 \text{ to } 0.1 \text{ mcg/kg/min} 0.05 to 0.1 mcg/kg/min . Once ductal patency is established (demonstrated by equalized upper and lower extremity pulses, improved systemic perfusion, and resolved metabolic acidosis), titrate down to a maintenance rate of 0.01 to 0.025 mcg/kg/min 0.01 \text{ to } 0.025 \text{ mcg/kg/min} 0.01 to 0.025 mcg/kg/min .

Warning

PGE1-Induced Apnea: Alprostadil induces sudden central apnea in 10% to 12% of neonates, usually within the first hour of infusion initiation. The clinical team must have endotracheal intubation equipment and emergency airway drugs immediately available at the bedside before starting PGE1.

Hemodynamic Profiles: Cold Shock vs. Warm Shock in Pediatric Sepsis

Unlike adult septic shock, which presents almost universally as hyperdynamic "warm shock" with high cardiac output and profound peripheral vasodilation ( S V R ↓ SVR \downarrow S V R ↓ ), community-acquired pediatric septic shock presents predominantly as hypodynamic "Cold Shock" in 60% to 70% of cases.

Hemodynamic Parameter Cold Shock (~65% of Pediatric Sepsis) Warm Shock (~35% of Pediatric Sepsis)

Primary Pathology Myocardial depression + intense compensatory vasoconstriction Profound peripheral vasodilation + low vascular tone

Cardiac Output / Index Low ( C I < 3.3 L/min/m 2 CI < 3.3 \text{ L/min/m}^2 C I < 3.3 L/min/m 2 ) High ( C I > 5.5 L/min/m 2 CI > 5.5 \text{ L/min/m}^2 C I > 5.5 L/min/m 2 )

  • Systemic Vascular Resistance High ( S V R ↑ SVR \uparrow S V R ↑ ) Low ( S V R ↓ SVR \downarrow S V R ↓ )
  • Extremities Cold, clammy, mottled, pale Warm, flushed, dry
  • Capillary Refill Time Prolonged (>2 seconds; often >4–5 seconds) Flash (<1 second)
  • Peripheral Pulses Diminished, thready, or absent Bounding, brisk

Pulse Pressure Narrow ( S B P − D B P ↓ SBP - DBP \downarrow SBP − D BP ↓ , e.g., 82/64 mmHg) Wide ( S B P − D B P ↑ SBP - DBP \uparrow SBP − D BP ↑ , e.g., 85/35 mmHg)

  • First-Line Vasoactive Agent Epinephrine (0.05–0.3 mcg/kg/min) Norepinephrine (0.05–0.3 mcg/kg/min)
  • Initial Fluid Resuscitation Protocols & Fluid Overload Risks
  • Balanced Crystalloids vs. 0.9% Normal Saline

Current pediatric consensus guidelines (Surviving Sepsis Campaign Pediatric Guidelines) strongly recommend balanced crystalloids (e.g., Plasma-Lyte A , Lactated Ringer's ) over 0.9% Normal Saline for acute shock resuscitation.

The Hyperchloremic Acidosis Danger: Normal saline contains 154 mEq/L of chloride , drastically exceeding normal plasma chloride concentrations ( 98 to 106 mEq/L ). Infusing large volumes of 0.9% NaCl induces hyperchloremic metabolic acidosis , triggers renal afferent arteriolar vasoconstriction, lowers renal cortical perfusion, reduces glomerular filtration rate, and significantly increases the incidence of acute kidney injury (AKI).

Fluid Administration Mechanics

Dosing: Administer 10 to 20 mL/kg aliquots of balanced crystalloid.

Rate: Infuse rapidly over 10 to 20 minutes via push-pull syringe technique or pressure-bag delivery through the largest gauge vascular access.

Reassessment Mandate: Perform focused clinical reassessment after each fluid bolus:

Assess heart rate, capillary refill, mental status, peripheral pulse volume, and urine output.

Stop Fluid Boluses Immediately if signs of fluid overload or cardiac failure develop:

Development of new or worsening hepatomegaly (palpate liver edge prior to and following every bolus).

New bilateral pulmonary crackles (rales) or worsening work of breathing.

New cardiac gallop rhythm ( S 3 S_3 S 3 ​ ) .

Fluid Overload Quantification & Morbidity Thresholds

In pediatric critical care, aggressive fluid administration without physiological clearance results in cumulative fluid overload. Cumulative fluid overload exceeding 10% to 15% independently correlates with a doubling of pediatric ICU mortality, increased days on mechanical ventilation, and escalated needs for continuous renal replacement therapy (CRRT). Cumulative Fluid Overload (%) = [ Total Fluid Intake (L) − Total Fluid Output (L) PICU Admission Weight (kg) ] × 100 % \text{Cumulative Fluid Overload (\%)} = \left[ \frac{\text{Total Fluid Intake (L)} - \text{Total Fluid Output (L)}}{\text{PICU Admission Weight (kg)}} \right] \times 100\% Cumulative Fluid Overload (%) = [ PICU Admission Weight (kg) Total Fluid Intake (L) − Total Fluid Output (L) ​ ] × 100%

Clinical Calculation Example: A 20 kg child has a cumulative 48-hour fluid intake of 5.8 L and total urine/drain output of 3.2 L: Net Fluid Balance = 5.8 L − 3.2 L = 2.6 L ( 2.6 kg ) \text{Net Fluid Balance} = 5.8 \text{ L} - 3.2 \text{ L} = 2.6 \text{ L} (2.6 \text{ kg}) Net Fluid Balance = 5.8 L − 3.2 L = 2.6 L ( 2.6 kg ) Fluid Overload = ( 2.6 20 ) × 100 % = 13 % ( Exceeds the 10% high-risk threshold ) \text{Fluid Overload} = \left( \frac{2.6}{20} \right) \times 100\% = 13\% \quad (\text{Exceeds the 10\% high-risk threshold}) Fluid Overload = ( 20 2.6 ​ ) × 100% = 13% ( Exceeds the 10% high-risk threshold )

Vasoactive & Inotropic Selection in Fluid-Refractory Shock

When shock signs (hypoperfusion, delayed/flash capillary refill, altered mentation, oliguria) persist despite 40 to 60 mL/kg of fluid resuscitation—or immediately if signs of fluid overload develop—vasoactive infusions must be initiated without delay. Vasoactive Selection Algorithm for Pediatric Fluid-Refractory Shock:

  • [Fluid-Refractory Shock]
  • │
  • ┌─────────────────┴─────────────────┐
  • ▼ ▼
  • [COLD SHOCK] [WARM SHOCK]
  • (Low CO, High SVR, Narrow PP) (High CO, Low SVR, Wide PP)
  • │ │
  • ▼ ▼
  • [FIRST-LINE: EPINEPHRINE] [FIRST-LINE: NOREPINEPHRINE]
  • (0.05-0.3 mcg/kg/min) (0.05-0.3 mcg/kg/min)
  • │ │
  • Persistent Cold Shock Persistent Warm Shock
  • │ │
  • ▼ ▼

Add Inodilator: Add Vasoconstrictor:

  • [MILRINONE] [VASOPRESSIN]
  • (0.25-0.75 mcg/kg/min, NO bolus) (0.0003-0.002 units/kg/min)
  • │ │
  • └─────────────────┬─────────────────┘
  • │
  • ▼
  • [Refractory Catecholamine-Resistant Shock]
  • │
  • ▼
  • [STRESS-DOSE HYDROCORTISONE]
  • (50-100 mg/m2/day or 1-2 mg/kg/day q6h)
  • Detailed Vasoactive Pharmacology Matrix

Drug Primary Receptors Hemodynamic Actions Clinical Dosing Range Pediatric Clinical Pearls

Epinephrine β 1 , β 2 \beta_1, \beta_2 β 1 ​ , β 2 ​ (low dose);; α 1 , β 1 \alpha_1, \beta_1 α 1 ​ , β 1 ​ (high dose) Inotrope, chronotrope, systemic vasoconstrictor at high doses; increases C O CO CO and D O 2 DO_2 D O 2 ​ 0.05–0.3 mcg/kg/min ; (Titrated up to 1 mcg/kg/min in severe shock) First-line for Cold Septic Shock and Cardiogenic Shock. At ≤ 0.05 \le 0.05 ≤ 0.05 mcg/kg/min, β 2 \beta_2 β 2 ​ vasodilation predominates; at > 0.1 >0.1 > 0.1 mcg/kg/min, α 1 \alpha_1 α 1 ​ vasoconstriction supports diastolic pressure. Stimulates skeletal muscle β 2 \beta_2 β 2 ​ receptors causing transient, benign aerobic hyperlactatemia (distinguish from hypoperfusion lactate).

Norepinephrine α 1 ≫ β 1 \alpha_1 \gg \beta_1 α 1 ​ ≫ β 1 ​ Potent systemic vasoconstriction with modest inotropy; increases S V R SVR S V R , increases MAP, improves coronary perfusion 0.05–0.3 mcg/kg/min ; (Titrated up to 1 mcg/kg/min) First-line for Warm Distributive Septic Shock. Effectively restores diastolic blood pressure and vascular tone without inducing excessive tachycardia.

Dopamine DA 1 \text{DA}_1 DA 1 ​ (1–3);; β 1 \beta_1 β 1 ​ (3–10);; α 1 \alpha_1 α 1 ​ (>10 mcg/kg/min) Variable inotropy and vasoconstriction depending on conversion to norepinephrine 5–20 mcg/kg/min Relegated to Second-Line. Relies on endogenous conversion to norepinephrine; in neonates and young infants, dopamine clearance is erratic and sympathetic nerve terminals are immature. Pediatric trials (Carcillo et al., Venturini et al.) revealed significantly higher 28-day mortality and infection rates compared to epinephrine.

Milrinone Phosphodiesterase-3 (PDE3) Inhibitor "Inodilator": positive inotrope, enhances lusitropy (diastolic relaxation), induces systemic & pulmonary vasodilation ( S V R ↓ , P V R ↓ SVR \downarrow, PVR \downarrow S V R ↓ , P V R ↓ ) Maintenance: 0.25–0.75 mcg/kg/min .; (Loading dose of 50 mcg/kg over 30–60 min is OMITTED in shock) Second-line inotrope for persistent cold shock with high SVR or post-cardiac surgery. Does not depend on β \beta β -adrenergic receptors. Renally cleared (85–90% unchanged) : clearance drops dramatically in AKI, expanding half-life from 1.5–2 hours to 6–12+ hours; reduce maintenance infusion by 50% to 75% in renal failure.

Vasopressin V 1 a V_{1a} V 1 a ​ vascular receptors Pure non-adrenergic vasoconstrictor; preserves coronary and cerebral perfusion; restores vascular tone in acidosis 0.0003–0.002 units/kg/min ; (0.018–0.12 units/kg/h) Adjunct for catecholamine-refractory warm shock. Effective when adrenergic receptors are down-regulated or desensitized by severe metabolic acidosis. Monitor for peripheral extravasation necrosis, splanchnic ischemia, and hyponatremia ( V 2 V_2 V 2 ​ antidiuretic effect).

Catecholamine-Refractory Shock & Corticosteroid Therapy

When shock persists despite high-dose catecholamines (e.g., epinephrine or norepinephrine requirements exceeding > 0.3 to 0.5 mcg/kg/min >0.3 \text{ to } 0.5 \text{ mcg/kg/min} > 0.3 to 0.5 mcg/kg/min ), the patient has catecholamine-resistant shock . A major contributor is Critical Illness-Related Corticosteroid Insufficiency (CIRCI) , caused by hypothalamic-pituitary-adrenal (HPA) axis exhaustion, blunted corticotropin release, down-regulated glucocorticoid receptors, and suppressed adrenal cortisol synthesis.

Stress-Dose Hydrocortisone Protocol

Indication: Fluid-refractory, catecholamine-resistant septic shock.

Dosing Strategies:

BSA-Based Dosing: 50 to 100 mg/m²/day IV divided every 6 hours.

Weight-Based Dosing: 1 to 2 mg/kg/day IV divided every 6 hours (up to a maximum of 50 mg per dose or 200 mg/day).

Mechanism of Action: Hydrocortisone possesses balanced glucocorticoid and mineralocorticoid activity. It upregulates cell-surface α 1 \alpha_1 α 1 ​ and β 1 \beta_1 β 1 ​ adrenergic receptor density, inhibits inducible nitric oxide synthase (iNOS), restores vascular responsiveness to infused catecholamines, and attenuates pathological systemic capillary leak.

Clinical Weaning: Baseline random cortisol levels and ACTH stimulation tests are not required to initiate therapy in refractory shock. Once vasoactive infusions are successfully weaned and shock resolves, hydrocortisone should be rapidly tapered over 2 to 4 days to prevent secondary immunosuppression, hyperglycemia, and opportunistic infection.